Compare PRCH & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PRCH | ABCL |
|---|---|---|
| Founded | 2012 | 2012 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2019 | 2020 |
| Metric | PRCH | ABCL |
|---|---|---|
| Price | $10.16 | $5.38 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 5 |
| Target Price | ★ $18.63 | $8.40 |
| AVG Volume (30 Days) | 2.3M | ★ 8.5M |
| Earning Date | 04-28-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 90.91 | 10.91 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $482,414,000.00 | $75,128,000.00 |
| Revenue This Year | $4.15 | N/A |
| Revenue Next Year | $17.05 | $21.85 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.18 | ★ 160.56 |
| 52 Week Low | $6.36 | $1.98 |
| 52 Week High | $19.44 | $6.52 |
| Indicator | PRCH | ABCL |
|---|---|---|
| Relative Strength Index (RSI) | 56.91 | 66.96 |
| Support Level | $8.93 | $5.34 |
| Resistance Level | $10.85 | $5.63 |
| Average True Range (ATR) | 0.57 | 0.43 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 34.46 | 87.28 |
Porch Group Inc is a vertical software company reinventing the home services and insurance industries. It has four reportable segments: Insurance Services, Software & Data, Consumer Services, and Corporate. The majority of revenue is from the Insurance segment. The Insurance Services segment manages and operates the Reciprocal, providing services related, but not limited, to underwriting, policy renewal, risk management, insurance portfolio management, financial management, and setting investment guidelines in exchange for commissions and fees.
AbCellera Biologics Inc is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody medicines for indications with high unmet medical need. It has built a platform for advancing antibody drug programs that the company believes provides it with a competitive advantage in addressing challenging, high-value targets such as complex transmembrane proteins and novel modalities, including multispecifics and antibody-drug conjugates. Organisation's pipeline includes two drug candidates in clinical development, two development candidates in Investigational New Drug (IND/Clinical Trial Application (CTA)-enabling activities, and more than 20 active discovery programs across multiple modalities and indications.